Mapping Human Papillomavirus, Epstein-Barr Virus, Cytomegalovirus, Adenovirus, And P16 In Laryngeal Cancer

Alexandra Schindele (alexandra.schindele@umu.se)
Umeå University  https://orcid.org/0000-0003-0007-8716

Anna Holm
Umeå University  https://orcid.org/0000-0003-3522-1842

Karin Nylander
Umeå University  https://orcid.org/0000-0002-4831-4100

Annika Allard
Umeå University  https://orcid.org/0000-0001-6949-1213

Katarina Olofsson
Umeå University  https://orcid.org/0000-0002-0649-3825

Research Article

Keywords: cancer, adenovirus, EBV, HCMV

Posted Date: January 5th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1225790/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Purpose: Apart from tobacco and alcohol, viral infections are proposed as risk factors for laryngeal cancer. The occurrence of oncogenic viruses including human papilloma virus (HPV) and Epstein-Barr virus (EBV), in laryngeal squamous cell carcinoma (LSCC) varies in the world. Carcinogenesis is a multi-step process, and the role of viruses in LSCC progression has not been clarified. We aimed to analyze the presence and co-expression of HPV, EBV, human cytomegalovirus (HCMV) and human adenovirus (HAdV) in LSCC. We also investigated if p16 can act as surrogate marker for HPV in LSCC.

Methods: Combined PCR/microarrays (PapilloCheck®) were used for detection and genotyping of HPV DNA, real time-PCR for EBV, HCMV and HAdV DNA detection, and EBER in situ hybridization (EBER-ISH) for EBV detection in tissue from 78 LSCC patients. Additionally, we analyzed p16 expression with immunohistochemistry.

Results: Thirty-three percent (26/78) of LSCC tumor samples were EBV positive, 9% (7/78) HCMV positive and 4% (3/78) HAdV positive. Due to DNA fragmentation, 45 samples could not be analyzed with PapilloCheck®; 9% of the remaining (3/33) were high-risk HPV16 positive and also over-expressed p16. A total of 14% (11/78) of the samples over-expressed p16.

Conclusion: These findings present a mapping of HPV, EBV, HCMV and HAdV, including the HPV surrogate marker p16, in LSCC in this cohort. Except for EBV, which was detected in a third of the samples, data show viral infection to be uncommon, and that p16 does not appear to be a specific surrogate marker for high-risk HPV infection in LSCC.

Introduction

Laryngeal cancer is detrimental for voice and airway, leading to life-changing consequences. The worldwide annual incidence of newly detected laryngeal cancer is 210000 cases/year. The estimated prevalence is ~1000000 cases/year and 126000 deaths/year [1]. Laryngeal squamous cell carcinoma (LSCC) can develop from several causes, with tobacco and alcohol use being recognized risk factors [2]. Other proposed risk factors are viral infections. Human papillomavirus (HPV), Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), and human adenovirus (HAdV) all replicate in the airway epithelium. They are transmitted via saliva or inhalation of droplets from infected individuals and can establish persistent infections in their host in part through evading host immune surveillance. Both HPV and EBV are associated with cancer in humans, including in the upper airway [3].

Cancer in the tonsils and base of tongue is associated with high-risk HPV genotypes HPV16 and HPV18. These types of cancer differ from non-HPV associated malignancies both biologically and clinically [4], which has led to adjustments in tumor classification. The presence of high-risk HPV types in LSCC has been reported in 5-24 % of cases [5]. Variations in HPV types and reporting are due to regional differences related to exposure as well as the use of different methods for identifying HPV types.
p16 is the second most common tumor suppressor gene [6], and its protein expression has been shown to be a reliable surrogate marker for HPV-infection in tonsillar cancer [7], whereas expression of p16 in mobile tongue cancer has no demonstrated correlation with HPV-infection [8].

EBV, on the contrary, downregulates p16 expression by suppressing the p16 gene promoter via latent membrane protein 1 (LMP-1) [6].

EBV is well established as a factor in B cell and epithelial malignancies, encoding oncogenes such as EBV encoded nuclear antigens, (EBNA 1-3) and LMP1-2. In nasopharyngeal cancer type 2 and 3, and in oral cancer, EBV has an established contributing role [3]. EBV is also reported in 60 % of laryngeal cancers [9].

EBV and HPV can each lead to cancer development independently, but these viruses can also co-infect and enhance cancer progression through interactions with other mechanisms [3]. HCMV and HAdV have molecular mechanisms that aid in cell transformation [10]. HCMV and HAdV infections can be devastating in immunocompromised patients. HCMV is not a typical human tumor virus but is thought to have oncomodulatory activity [4]. The common cold virus HAdV is not known to have oncogenic potential in humans, but its early gene products can transform rodent cells [11].

Carcinogenesis is a multistep process, and the role of viruses in this progression in LSCC has not been fully identified. If viruses turn out to be important in development of LSCC, anti-viral vaccines could potentially be used for prevention, and possibly even treatment of this disease. Vaccination holds a promise for a vast reduction of HPV-related cancer in tonsils and base of tongue. Our hypothesis is that LSCC is associated with oncogenic/oncomodulatory virus. Therefore, our purpose is to map HPV, EBV, HCMV and HAdV in a group of cases with LSCC, and study co-infection. In addition, we aim to analyze if p16 is a reliable surrogate marker for HPV in LSCC.

**Materials And Methods**

*Materials*

We identified 236 consecutive LSCC samples from cases between 2000 and 2017 in SymPathy (Tieto, Finland). Slides were histopathologically re-examined (by KN and KO) for correct diagnosis and classification of cancer site.

Exclusion criteria for analysis were: 1) repeated biopsies from the same case (112 samples), 2) previous radiotherapy to the neck (39 samples), 3) classification errors (5 samples) and 4) too little tumor tissue for analysis (2 samples).

*Patient characteristics*

SymPathy data provided access to clinical chart databases to supplement patient characteristics.
Descriptive data presented in two groups

Descriptive data on 78 LSCC samples included in the PCR analysis of EBV, HCMV, HAdV and p16 (analyzed by IHC) are presented. Due to HPV DNA fragmentation, 45 LSCC samples could not be analyzed, and were therefore drop-outs in the HPV PCR results (Figure 1). To clarify the possible impact of the dropouts, we analyzed the dropout group separately in categories for age, sex, LSCC site (supraglottic, glottic, subglottic) and smoking status (non-smoker, former smoker, smoker) (Table 1).

Table 1. Case characteristics.

Results presented in numbers and proportion (in brackets). SD = standard deviation presented in square brackets.
| Characteristics | Total group n =78 (%) | HPV subgroup n=33 (%) |
|-----------------|----------------------|----------------------|
| **Age**         |                      |                      |
| Mean [SD]       | 68.1 [±10.3]         | 67.2 [±10.2]         |
| Range           | 41–86                | 46–83                |
| **Sex**         |                      |                      |
| Female          | 15 (19)              | 6 (18)               |
| Male            | 63 (81)              | 27 (82)              |
| **Site**        |                      |                      |
| Supraglottic    | 12 (15)              | 5 (15)               |
| Glottic         | 64 (82)              | 27 (82)              |
| Subglottic      | 2 (3)                | 1 (3)                |
| **Smoking status** |                  |                      |
| Non-smoker      | 14 (18)              | 6 (18)               |
| Female          | 4 (5)                | 2 (6)                |
| Male            | 10 (13)              | 4 (12)               |
| Former smoker   | 21 (27)              | 8 (24)               |
| Female          | 3 (4)                | 1 (3)                |
| Male            | 18 (23)              | 7 (21)               |
| Smoker          | 42 (54)              | 19 (58)              |
| Female          | 7 (9)                | 3 (9)                |
| Male            | 35 (45)              | 16 (49)              |
| Smoking data missing | 1 (1)              | -                    |

**Cases**

Seventy-eight (78) LSCC samples were assessed for eligibility. The case ages ranged from 41-86 with a mean of 68.1 years (± 10.3). The sex distribution was 15 (19%) women and 63 (81%) men, and other clinical characteristics are shown in Table 1.

**HPV subgroup**

Thirty-three LSCC samples underwent HPV genotyping, with an age range of 46-83, mean of 67.2 years (± 10.2). The sex distribution was 6 (18%) women and 27 (82%) men.
Methods

Combined PCR/microarrays (PapilloCheck®, Greiner BioOne GmbH, Frickenhausen, Germany) were used for detection and genotyping of HPV and real-time PCR for EBV, HCMV and HAdV DNA detection. EBER in situ hybridization (EBER-ISH) was used for EBV detection in slides from LSCC tumors. In addition, we used immunohistochemistry (IHC) for mapping of p16 (Figure 1).

**PCR for HPV, EBV, HCMV and HAdV**

DNA was prepared by cutting five 10-µM sections from each LSCC biopsy followed by routine extraction using the QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany). Quality and quantity of total DNA was measured spectrophotometrically.

HPV detection by PapilloCheck® requires a DNA fragment of 350 bp for successful PCR performance. To assess the degree of DNA fragmentation prior to detection and typing using the PapilloCheck®, we performed three different PCR assays amplifying amplicon lengths of 536, 268 or 100 bp of the β-globin housekeeping genes, and one real-time PCR assay detecting 60 bp of the RNasP housekeeping gene.

The PapilloCheck® is a multiplex PCR method with fluorescent primers, for genotyping of 24 HPV-types including 18 high-risk HPV types; HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82, and six low-risk HPV types; HPV 6, 11, 40, 42, 43, and 44.

For EBV detection, a real-time PCR assay of the *BamHI*-W region of the EBV genome was used. The sequences of the forward and reverse primers were 5'-GCATAATGGCGGACCTAGG-3' and 5'-AAGATAGCAGCAGCAGCAGC-3', respectively, flanking the dual-labelled probe 5'- (FAM)TAAAACCCCAGGAAGCCGTATG(TAMRA)-3'. Real-time PCR detection towards the polymerase gene of HCMV consisted of the amplification primers 5'- TGDGTACGCGCTTCTCTAG - 3' and a 50:50 mix of 5' - ATCATGTCAGCCGACAATGACAGCT - 3' and 5' - ATCATGTCAGGCAGCTACACTGG - 3', flanking the dual-labelled fluorescent probe 5'- (FAM)ACTCGCCACCGGCACCAAC(TAMRA) - 3'.

Qualitative real-time PCR for the detection of HAdV was performed as described by Hernroth et al. [12].

**EBER-ISH for EBV mapping**

The EBER-ISH is an in-situ hybridization kit for EBER transcripts (Epstein-Barr Encoding Region), and this was applied for EBV mapping in tumor and connective tissue.

Two tissue sections were cut from each LSCC biopsy, one was incubated with an RNA-positive control probe (800-2846, Ventana). The second section was tested for EBER-1 and EBER-2 by the Inform EBER Probe (800-2842, Ventana Medical Systems, Roche Diagnostics GmbH, Mannheim Germany). NBT-BCIP Detection System (800-092, Roche Diagnostics GmbH, Mannheim, Germany) was employed for visualization. We used a Ventana BenchMark ULTRA system (Roche Diagnostics AG, Switzerland) for staining.
EBER-positive cells were counted in tumor and connective tissue by three of the authors (AS, AH and KN). Consensus was reached after comparison of individual results.

EBER was graded as positive when there were $\geq 2$ positive cells and graded as negative when there were one or no positive cells.

*p16 immunohistochemistry (IHC) and Quickscore analysis*

To detect the p16 protein, five µm sections were cut from paraffin blocks. The staining system (Ventana BenchMark ULTRA, Roche Diagnostics AG, Switzerland) was applied, and slides pretreated in CC1 (cell condition solution 1, pH 8.4; Ventana) for 48 minutes. For detection of p16, CINtec® p16 Histology (Roche Diagnostics AG, Switzerland) was used. To visualize the antibody, the Opti View DAB IHC Detection Kit (Ventana Medical Systems) was employed.

p16 expression was evaluated by three members of the group (AS, AH and KN) using a light microscope (Nikon Eclipse Ci, Tokyo, Japan) and a semiquantitative Quickscore system by Detre et al. [13]. Using this system, we evaluated both proportion of p16 stained cells and the staining intensity (see Supplementary Information). Multiplying the scores for proportion of stained cells with intensity, results in a Quickscore ranging from 0–18. After comparison rounds consensus was reached.

*Statistics*

Descriptive statistics (IBM SPSS USA, version 26) were presented regarding age, gender, smoking, cancer site and presence of virus and p16. Cross tabulations were used to describe numbers and proportions of virus and p16. The association between virus and p16 were analyzed using Chi-square test and Fisher’s exact test. A probability value of equal or less than 0.05 (2-sided) was considered statistically significant.

*Results*

*HPV*

HPV was assessed in a two-step fashion. First, 45 samples were excluded due to DNA fragmentation, exhibiting fragments smaller than the 350 bp needed for successful detection and typing. To ensure correct sorting, an HPV analysis with PapilloCheck® was performed on these excluded samples, without adding new results. Real-time PCR of the endogenous target gene RNAsP indicated that all samples contained DNA of at least 60 bp.

Secondly, we performed PapilloCheck® on a sub-group of 33 samples. Nine percent (3/33) were high-risk HPV16 positive (Table 2).

Table 2. EBV, HCMV, HAdV and HPV in LSCC samples. Results presented in numbers and proportion (in brackets).
Two of three HPV16 positive cancers were in the true vocal cords, both patients were females and one also a smoker. The third patient was a non-smoking male with subglottic cancer. We did not identify any imbalance comparing the sub-group (n=33) to the group in total (n=78) regarding age, sex, site, or smoking status.

**HPV and co-infections**

One patient was positive for both HPV and EBV (1/33), whereas 15/33 were EBV positive, but HPV negative (Table 3).

Table 3. Viral co-infections in LSCC samples.

Results presented in numbers and proportion (in brackets). None of the patients had infection with more than two viruses simultaneously.

| Co-infection | Positive (%) | Negative (%) | p-value |
|--------------|--------------|--------------|---------|
| HPV + EBV    | 1 (3)        | 17 (52)      | p = 1.00|
| HPV + HCMV   | 0            | 27 (82)      | p = 1.00|
| HPV + HAdV   | 0            | 28 (85)      | p = 1.00|
| EBV + HCMV   | 5 (6)        | 50 (64)      | p ≤ 0.038|
| EBV + HAdV   | 1 (1)        | 50 (64)      | p = 1.00|
| CMV + HAdV   | 1 (1)        | 69 (88)      | p = 0.25|

a Analyzed in HPV subgroup n = 33

**HPV and p16**

The three HPV16 positive samples had a p16 QS of 12 (1) and 18 (2).
**EBV**

We detected EBV by PCR in 33 % (26/78), comprising tumor and connective tissue. Thereafter, EBER-ISH revealed distribution of EBER-positive cells in the tissue (Figure 2).

The amount of positive cells/slide ranged from 2-10, with a mean of 5 cells in tumor tissue and 4.6 cells in connective tissue. Five percent (4/78) of samples were EBER-positive in tumor tissue, and 6% (5/78) were EBER-positive in connective tissue. Two of these samples were EBER-positive in both tumor and connective tissue, thus 9% (7/78) of LSCC samples were EBER-positive (Table 4).

Table 4. EBER-stained cells in tumor and/or connective tissue in LSCC samples. Results presented in numbers and proportion (brackets).

| EBER-stained cells in LSCC samples | Positive (%) | Negative (%) |
|-----------------------------------|--------------|--------------|
| EBER-stained cells in tumor       | 4 (5)        | 74 (95)      |
| EBER-stained cells in connective tissue | 5 (6)    | 73 (94)      |
| EBER in tumor + connective tissue | 2 (3)        | 76 (97)      |
| EBER-stained cells in total of 78 samples | 7 (9)    | 71 (91)      |

**HCMV and HAdV**

Nine percent (7/78) were HCMV positive and 4 % (3/78) of samples were HAdV positive (Table 2).

**EBV, HCMV and HAdV co-infections**

**EBV and HCMV**

Six percent (5/78) of samples were positive for both EBV (PCR) and HCMV (Table 3).

**EBV and HAdV**

One percent (1/78) of the samples were positive for both EBV and HAdV (Table 3).

**CMV and HAdV**

One percent (1/78) of the samples were positive for both HCMV and HAdV (Table 3).

**p16**

The analysis of p16 in tumor tissue for intensity and proportion showed a Quickscore (QS) ranging from 0-18 (Figure 3).
We ranked our Quickscore results in three groups: negative QS (QS=0), low QS (QS=1 and 2) and high QS (QS=3-18). The results were: negative QS = 42% (33) of samples, low QS = 44 % (34) and high QS 14% (11) of samples (Table 5). Nine percent (3/33) were HPV16 positive, and 58% (45/78) of LSCC samples expressed p16.

Table 5. p16 Quickscore ranking groups. Results presented in numbers and proportion (in brackets).

| p16 Quickscore-groups | Numbers (%) |
|-----------------------|-------------|
| Negative QS           | 33 (42)     |
| Low QS                | 34 (44)     |
| High QS               | 11 (14)     |
| Total                 | 78 (100)    |

**Discussion**

We performed a complete mapping of four different viruses and p16 in the same group of cases with LSCC, which showed that 33% (26/78) of samples were EBV infected and 9% (3/33) were high-risk HPV16 positive. These oncogenic viruses were expressed individually; in one case only (of 33) co-expression was noted.

Three out of 11 p16 high QS samples correlated with high-risk HPV16 positive samples, indicating that p16 was not a very sensitive surrogate marker for HPV16 in LSCC.

The common upper airway viruses HCMV and HAdV, were present in low amounts; 9% (7/78) were HCMV positive and 4% (3/78) HAdV positive. It would be relevant to map the same viruses in non-tumorous laryngeal mucosa, but ethical consideration makes it impossible to collect samples from a healthy control group, as the true vocal cords are susceptible to injuries in this type of sampling process.

**HPV**

We searched for high- and low risk HPV types with PapilloCheck® in 33 LSCC samples. Nine percent (3/33) were high-risk HPV16 positive. Remaining 45 samples could not be analyzed due to random fragmentation of DNA caused by aging. Comparison of the groups did not show any differences regarding age, sex, site, or smoking status.
PapilloCheck® is a readily available, sensitive, and robust technique, used routinely in the clinical setting for screening of high and low-risk HPV types in the cervix. E6/E7 mRNA technique is by some considered a reference diagnostic test of active HPV infection [14] [5]. However, the commercially available E6/E7 mRNA tests have reduced capacity to detect multiple HPV genotypes.

Regardless of the detection method, HPV positivity appears to be low in LSCC. E6/E7 mRNA expression is reported between 2%-8.6% [14] [15], and HPV DNA <10% in LSCC [5]. This is coherent with our findings of 9% positive HPV16 in our Northern Swedish cohort.

**EBV**

Using multidimensional outcome measures, we first found EBV by PCR in 33% of the tumor samples. Secondly, mapping of EBER-stained cells revealed roughly equal distribution in tumor (5%) and adjacent connective tissue (6%). EBER-ISH is not a quantitative measure, but it can map location of the EBV-infected cells in one slice of the total tissue sample. Epstein-Barr Encoded Regions 1 and 2 (EBERs) are good markers of EBV infection and present in numerous copies in latently EBV-infected cells. They are easily identified by in situ hybridization (ISH) [16]. EBERs are thought to aid in the activation of oncogenic signaling pathways [17].

EBV PCR, on the contrary, was used to assess EBV presence or absence in a bigger piece (2x2 mm) of the tumor. This explains the different numeric results between PCR and EBER-ISH.

It is important to distinguish EBV in actual tumor epithelial cells vs non-tumor cells, since EBV infection of epithelial cells is considered pathological [18]. It is unclear if EBER in connective tissue is clinically significant, and analysis by PCR therefore implies the risk of detecting virus in the whole tissue sample, without being tumor specific. Whether our finding of EBER-stained cells in epithelial tumor tissue represents an oncogenic effect of EBERs in LSCC, can only be a matter of speculation.

**HPV and EBV co-infection**

We found one patient (1/33) positive for both HPV and EBV in LSCC samples. EBV is known to interact with HPV in adult-onset recurrent respiratory papillomatosis, a benign lesion on the vocal folds with a risk of malignant conversion [19]. In LSCC in a Polish population, co-infection with HPV (36%), EBV (60%) and HCMV (12%) was reported [9]. Furthermore, Jiang et al. found co-infection of HPV and EBV in tonsillar (25%) and base of tongue (70%) cancer [20]. However, it is still not certain whether simultaneous HPV and EBV presence in carcinoma tissue of the upper airway simply reflects a coincidental infection or has an additive effect on carcinogenesis.

**HCMV and HAdV**

One of the target viruses in the analysis, HCMV, might have "oncomodulatory" activities, resulting in secretion of cellular and viral growth factors and cytokines in tumor microenvironment [3]. Nine percent (7/78) were HCMV positive, and 6% (5/78) both HCMV and EBV positive. None of the LSCC samples was
HCMV and HPV positive. Although implicated as a cofactor in HPV-mediated carcinogenesis, an association between oral cancer and HCMV has not yet been identified [21].

The second target virus, HAdV, confers mild and self-limiting infections such as the “common cold”. HAdV is oncogenic in rodents, but oncogenicity has not been observed in humans [22]. Humans can mount an immune response against HAdV-transformed cells [10]. Data showed 4% HAdV positivity. Two samples were co-infected with HAdV and EBV or HCMV.

p16

There is not a widely accepted specific p16 cut-off value for positivity in the literature. The College of American Pathologists recommends that for positive diagnosis, p16 shows strong, diffuse nuclear and cytoplasmic staining in 70% of tumor cells [23].

We used the Quickscore (QS) method from Detre et al. [13] to assess p16 expression in tissue sections. This method takes into account the proportion of positively stained cells and multiplies it with the intensity of the staining. High p16 QS, defined as \( \geq 12 \), corresponds to 80-100% of tumor cells expressing p16, fulfilling the requirements of the above-mentioned guidelines.

The tumor suppressor protein p16 was expressed with high intensity and quantity in the HPV16 positive cancer samples, whereas 8 samples over-expressed p16 without any correlation to HPV16. This supports the interpretation that p16 is not a reliable surrogate marker for HPV infection in LSCC.

Oncogenicity

Whether HPV, EBV, HCMV and HAdV are just ‘passerby’ viruses in LSCC, or have oncogenic or oncomodulatory capacities, is a relevant clinical question. HPV and EBV have capabilities of virus-induced metabolic changes that share similarities with tumor associated metabolic reprogramming [10]. Metabolic reprogramming is probably an important feature of viral oncogenesis, together with modulation of cell cycle progression, resistance to cell death and evasion from immune surveillance. HCMV and HAdV, on the other hand, are upper airway viruses which may catalyze oncomodulatory effects, and are therefore relevant to study in LSCC.

Conclusion

This is the first thorough report mapping HPV, EBV, HCMV and HAdV, including p16, in the same group of patients with LSCC. Except for EBV, which was detected in a third of the LSCC samples, viruses were not found in a large proportion of cases with this tumor type in this cohort. The findings also demonstrate that p16 may not be reliable as a surrogate marker for high-risk HPV infection in LSCC.

Declarations

Funding
This study was supported by grants from FoU-enheten, Region Jämtland Härjedalen, Jämtlands Läns Cancer och Omvårdnadsfond, Cancer Research Foundation Northern Sweden account no LP 16-2020, CFF 17-2156, AMP 18-925, and Region Västerbotten account no RV938896.

**Conflicts of interest/Competing interests**

The authors report no conflicts of interest.

**Availability of data and material**

The data that support the findings of this study are available on request from the corresponding author.

**Code availability**

Not applicable.

**Authors’ contributions**

All authors contributed to the study conception and design, as well as material preparation, data collection and analysis. The first draft of the manuscript was written by Alexandra Schindele and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Ethics approval**

The study was approved by the Regional Ethical Review Board of Umeå University, Sweden, approval number 2010-277-31M (with addendum 2011-114-32M, 2012-276-32M, 2015-323-32M and 2017-543-32M). Samples were obtained with permission from the Biobank North (Västerbotten Regional Council 2018-05-09 (2013-03-26) approval number 472-13-008).

**Consent to participate**

Patients gave their consent for tissue banking and research prior to diagnostic surgery at the ENT clinics in northern Sweden.

**Consent for publication**

Not applicable.

**Acknowledgments**

We would like to thank Anna Lindam, PhD, for statistical advice, Irene Eriksson for laboratory work and Professor Michael Haney for text revision.

**References**
1. Nocini R, Molteni G, Mattiuzzi C, Lippi G. Updates on larynx cancer epidemiology. Chin J Cancer Res. 2020;32(1):18–25. https://doi.org/10.21147/j.issn.1000-9604.2020.01.03.

2. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541–50. https://doi.org/10.1158/1055-9965.EPI-08-0347.

3. Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res. 2017;231:139–47. https://doi.org/10.1016/j.virusres.2016.11.002.

4. Guidry JT, Birdwell CE, Scott RS. Epstein-Barr virus in the pathogenesis of oral cancers. Oral Dis. 2017. https://doi.org/10.1111/odi.12656.

5. Wittekindt C, Wuerdemann N, Gattenlohner S, Brobeil A, Wierzbicka M, Wagner S, et al. The role of high-risk human papillomavirus infections in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2017;274(11):3837–42. https://doi.org/10.1007/s00405-017-4718-1.

6. Serra S, Chetty R. p16. J Clin Pathol. 2018;71(10):853–8. https://doi.org/10.1136/jclinpath-2018-205216.

7. Loizou C, Laurell G, Lindquist D, Ofverman C, Stefansson K, Nylander K, et al. Incidence of tonsillar cancer in northern Sweden: Impact of human papilloma virus. Oncol Lett. 2015;10(6):3565–72. https://doi.org/10.3892/ol.2015.3775.

8. Sgaramella N, Coates PJ, Strindlund K, Loljung L, Colella G, Laurell G, et al. Expression of p16 in squamous cell carcinoma of the mobile tongue is independent of HPV infection despite presence of the HPV-receptor syndecan-1. Br J Cancer. 2015;113(2):321–6. https://doi.org/10.1038/bjc.2015.207.

9. Polz-Gruszka D, Stec A, Dworzański J, Polz-Dacewicz M. EBV, HSV, CMV and HPV in laryngeal and oropharyngeal carcinoma in Polish patients. Anticancer Res. 2015;35(3):1657–61.

10. Lévy P, Bartosch B. Metabolic reprogramming: a hallmark of viral oncogenesis. Oncogene. 2016;35(32):4155–64. https://doi.org/10.1038/onc.2015.479.

11. Ip WH, Dobner T. Cell transformation by the adenovirus oncogenes E1 and E4. FEBS Lett. 2020;594(12):1848–60. https://doi.org/10.1002/1873-3468.13717.

12. Hernroth BE, Conden-Hansson AC, Rehnstam-Holm AS, Girones R, Allard AK. Environmental factors influencing human viral pathogens and their potential indicator organisms in the blue mussel, Mytilus edulis: the first Scandinavian report. Appl Environ Microbiol. 2002;68(9):4523–33. https://doi.org/10.1128/aem.68.9.4523-4533.2002.

13. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876–8.

14. Taberna M, Resteghini C, Swanson B, Pickard RK, Jiang B, Xiao W, et al. Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma. Oral Oncol. 2016;61:55–61. https://doi.org/10.1016/j.oraloncology.2016.08.009.
15. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31. https://doi.org/10.1016/s1470-2045(14)70471-1.

16. Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods in molecular biology. (Clifton NJ). 2013;999:223–30. https://doi.org/10.1007/978-1-62703-357-2_16.

17. Yin H, Qu J, Peng Q, Gan R. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2019;208(5):573–83. https://doi.org/10.1007/s00430-018-0570-1.

18. Thorley-Lawson DA. EBV Persistence—Introducing the Virus. Curr Top Microbiol Immunol. 2015;390(Pt 1):151–209. https://doi.org/10.1007/978-3-319-22822-8_8.

19. Formánek M, Formánková D, Hurník P, Vrtková A, Komínek P. Epstein-Barr virus may contribute to the pathogenesis of adult-onset recurrent respiratory papillomatosis: A preliminary study. Clin Otolaryngol. 2020. https://doi.org/10.1111/coa.13681.

20. Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, et al. Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med. 2015;44(1):28–36. https://doi.org/10.1111/jop.12221.

21. Saravani S, Kadeh H, Miri-Moghaddam E, Zekri A, Sanadgol N, Gholami A. Human Cytomegalovirus in Oral Squamous Cell Carcinoma in Southeast of Iran. Jundishapur J Microbiol. 2015;8(8):e21838. https://doi.org/10.5812/jjm.21838.

22. Usman N, Suarez M. Adenoviruses. StatPearls. StatPearls Publishing; 2020. Copyright ©. 2020, StatPearls Publishing LLC, Treasure Island (FL).

23. Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lachetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018;142(5):559–97. https://doi.org/10.5858/arpa.2017-0286-CP.

**Figures**

**Figure 1**

Flowchart of LSCC samples for virus and p16 analysis

**Figure 2**

EBER *in situ* hybridization (EBER-ISH) applied for EBV mapping in tumor and connective tissue of a LSCC sample. Signals are detected as purple stained cells. EBER positive cells in tumor (black arrow) and...
connective tissue (white arrow)

**Figure 3**

Representative p16 immunohistochemistry (IHC) staining in a LSCC sample with high Quickscore = 18 (proportion: 6 x intensity: 3)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformationQuickscoresystembyDetreetal.docx](#)